113 related articles for article (PubMed ID: 8610647)
1. Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma.
Mani S; Todd M; Poo WJ
Am J Clin Oncol; 1996 Apr; 19(2):187-9. PubMed ID: 8610647
[TBL] [Abstract][Full Text] [Related]
2. Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma.
Mani S; Poo WJ
Am J Clin Oncol; 1996 Apr; 19(2):149-53. PubMed ID: 8610639
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.
Kankuri M; Pelliniemi TT; Pyrhönen S; Nikkanen V; Helenius H; Salminen E
Cancer; 2001 Aug; 92(4):761-7. PubMed ID: 11550145
[TBL] [Abstract][Full Text] [Related]
5. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
[TBL] [Abstract][Full Text] [Related]
8. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.
Gleave ME; Elhilali M; Fradet Y; Davis I; Venner P; Saad F; Klotz LH; Moore MJ; Paton V; Bajamonde A
N Engl J Med; 1998 Apr; 338(18):1265-71. PubMed ID: 9562580
[TBL] [Abstract][Full Text] [Related]
9. Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma.
Reese DM; Corry M; Small EJ
Cancer; 2000 Mar; 88(6):1310-6. PubMed ID: 10717611
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
Lopez Hänninen E; Kirchner H; Atzpodien J
J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
[TBL] [Abstract][Full Text] [Related]
11. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
Rinehart J; Malspeis L; Young D; Neidhart J
Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.
Hutson TE; Molto L; Mekhail T; Elson P; Finke J; Tannenbaum C; Borden E; Dreicer R; Olencki T; Bukowski RM
Clin Cancer Res; 2003 Apr; 9(4):1354-60. PubMed ID: 12684404
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma.
Buzaid AC; Robertone A; Kisala C; Salmon SE
J Clin Oncol; 1987 Jul; 5(7):1083-9. PubMed ID: 3598612
[TBL] [Abstract][Full Text] [Related]
16. alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients.
Atzpodien J; Poliwoda H; Kirchner H
Semin Oncol; 1991 Oct; 18(5 Suppl 7):108-12. PubMed ID: 1948123
[TBL] [Abstract][Full Text] [Related]
17. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
19. Treatment of renal cell carcinoma with escalating doses of alpha-interferon.
Tsavaris N; Mylonakis N; Bacoyiannis C; Tsoutsos H; Karabelis A; Kosmidis P
Chemotherapy; 1993; 39(5):361-6. PubMed ID: 8370327
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
